Commercial production of ciprofloxacin and omeprazole began in February 1996. Initially intending to manufacture para hydroxy phenyl glycine (PHPG), the company later decided to pivot due to market conditions, opting instead to increase the capacity of ciprofloxacin from 30 tpa to 120 tpa and to diversify into the production of enrofloxacin/naproxen. Additionally, the company boosted its installed capacity of Benzimidazole by 60 tpa, reaching a total of 120 tpa.
The capacity of Omeprazole Op Sulphide was also expanded from 15 TPA to 30 TPA. In 2007-08, the company expanded its product range with the introduction of Esomeprazole Magnesium, achieved through investments in new facilities and machinery.